Contents

Preface VII

Section 1  History and Clinical Diagnosis and Typing  1

Chapter 1  “Amyloid” — Historical Aspects  3
Maarit Tanskanen

Chapter 2  Diagnosis of Amyloidosis  25
Cezar Augusto Muniz Caldas and Jozelio Freire de Carvalho

Chapter 3  Cardiac Amyloidosis: Typing, Diagnosis, Prognosis and Management  33
Glenn K. Lee, DaLi Feng, Martha Grogan, Cynthia Taub, Angela Dispensieri and Kyle W. Klarich

Chapter 4  Dialysis-Related Amyloidosis: Pathogenesis and Clinical Features in Patients Undergoing Dialysis Treatment  67
Suguru Yamamoto, Junichiro James Kazama, Hiroki Maruyama and Ichiei Narita

Chapter 5  Ocular Presentations of Amyloidosis  85
Hesam Hashemian, Mahmoud Jabbarvand, Mehdi Khodaparast, Elias Khaililpour and Hamid Riazi Esfehani

Section 2  The Mechanism of the Disease  111

Chapter 6  Transthyretin-Related Amyloidoses: A Structural and Thermodynamic Approach  113
Estefania Azevedo, Priscila F. Silva, Fernando Palhano, Carolina A. Braga and Debora Foguel
Chapter 7  
Anti-Cytokine Therapy for AA Amyloidosis  131  
Keisuke Hagihara, Syota Kagawa, Yuki Kishida and Junsuke Arimitsu

Section 3  
The Advancement of Therapy  153

Chapter 8  
Treatment of End Stage Heart Failure Related to Cardiac Amyloidosis  155  
Tal Hasin, Eugenia Raichlin, Angela Dispenzieri and Sudhir Kushwaha

Chapter 9  
Diagnosis and Treatment of AA Amyloidosis with Rheumatoid Arthritis: State of the Art  187  
Takeshi Kuroda, Yoko Wada and Masaaki Nakano

Chapter 10  
Therapeutic Strategies in Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis  213  
Tadashi Nakamura
Dialysis-Related Amyloidosis: Pathogenesis and Clinical Features in Patients Undergoing Dialysis Treatment

Suguru Yamamoto, Junichiro James Kazama, Hiroki Maruyama and Ichiei Narita

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53390

1. Introduction

Amyloidosis is defined as an insoluble protein fibril that is deposited, mainly, in the extracellular spaces of organs and tissues as a result of a sequence of changes in protein folding. Precursor proteins change their conformation that forms amyloid fibrils, then deposited amyloid induce organ damage with disease specific conditions.

To date, there are 27 types of amyloidosis known extracellular fibril proteins in human, and each amyloidosis is characterized amyloid protein precursor, systemic (S) or localized organ (L), and syndrome or involved tissues [1]. In the nomenclature, dialysis-related amyloidosis (DRA) is defined as β2-microglobulin-related (Aβ2M) amyloid which precursor protein is β2-microglobulin (β2-m). It is associated to dialysis, a kidney replacement therapy, and deposits in systemic (S), mainly joint tissues [1].

Long-term dialysis treatment for end-stage kidney disease often induces the Aβ2-m amyloid deposition in mainly osteoarticular tissues that induces various disorders, such as carpal tunnel syndrome (CTS), destructive spondyloarthropathy (DSA), and cystic bone lesions as well as in systemic organs such as heart and gastrointestinal tract when disease advances. Several biomolecules including β2-m as well as clinical risk factors are thought to relate with Aβ2M amyloidogenesis (Figure 1). Recent progress of dialysis therapy has improved survival of dialysis patients, however, older age and long-term dialysis treatment may increase the onset and acceleration of DRA. In this article, we described about DRA focused on pathogenesis, clinical manifestations and treatment, and showed DRA is still one of serious complications for patients undergoing long-term dialysis treatment.
2. Pathogenesis of dialysis-related amyloidosis

2.1. $\beta_2$-microglobulin

$\beta_2$-m is a polypeptide of 99 residues that has a molecular weight of 11.8 kDa. It forms the beta chain of the human leukocyte antigen (HLA) class I molecule and has a well-known $\beta$-sandwich structure that involves a 7-strand $\beta$-pleated structure stabilized with a single disulphide

vitro condit:
(SDS) [4]. Proper dose amyloid fib

2.2. Retent

$\beta_2$-m is a co
$\beta_2$-m is non
catabolism serum due

Some clinic circulating | to end-stag intermedial
2.7±1.4 mg/
using a pol
decreased ti
[10]. These
difficult to
immobilize tissue (car

phy-mass :
cleaved anc
but not in
demonstrat
conformati
of DRA, an
fibrils form

2.3. A$\beta_2$-m :

A nucleatie
fibril forma
phases, i.e.,
steps of mo
step in am
addition of
extension o
association

In the med
of protein i
disulphide bond (Cys25-Cys80). β2-m changes the conformation under various in vivo or in vitro conditions, such as acidic pH [2], 2,2,2-trifluoroethanol (TFE) [3], sodium dodecyl sulfate (SDS) [4], lysophospholipids [5], non-esterified fatty acids [6], heating [7] and agitation [8]. Proper dose of those molecules induce conformational intermediate that is required for Aβ2M amyloid fibril formation/extension (see below section).

2.2. Retention of conformational intermediate-β2-m

β2-m is a component of MHC class I molecules, which are present on all nucleated cells. Most β2-m is normally eliminated by the kidney via glomerular filtration and subsequent tubular catabolism with Megalin [9]. Thus, severe kidney damage induces the retention of β2-m in serum due to impaired excretion from the kidney.

Some clinical studies have attempted to identify the conformational intermediate form of circulating β2-m. Capillary electrophoresis reveals that patients undergoing hemodialysis due to end-stage kidney disease, but not healthy control subjects, have the conformational intermediate form of β2-m in serum [10]. The level of predialysis serum β2-m intermediate was 2.7±1.4 mg/L and native β2-m was 29.4±6.8 mg/L in 31 hemodialysis patients. Hemodialysis using a polymethylmethacrylate and online hemodiafiltration with a polysulfone membrane decreased the level of the native form, while any change in the intermediate form was variable [10]. These results suggest that intermediate β2-m is increased in hemodialysis patients and is difficult to remove with dialysis treatment. It may suggest that the intermediate form is immobilized in the extracellular space where Aβ2-m amyloid has a marked affinity for joint tissues (cartilage, capsule, and synovium). In addition, immunoaffinity–liquid chromatography–mass spectrometry analysis and immunoassay revealed the generation of lysine-58-cleaved and truncated β2-m (ΔK58-β2-m), which was found in serum from 20–40% HD patients but not in serum from control subjects [11]. However, this truncated form has not been demonstrated in the tissue containing Aβ2-m amyloid [12]. It is not certain whether the conformational intermediate or the truncated form of β2-m has a critical role of onset/progress of DRA, and future studies will be needed to understand the pathogenesis for Aβ2-m amyloid fibrils formation/extension.

2.3. Aβ2-m amyloid fibril formation and extension

A nucleation-dependent polymerization model explains the general mechanisms of amyloid fibril formation in vitro, in various types of amyloidosis [13-18]. This model consists of two phases, i.e., nucleation and extension phases. Nucleus formation requires a series of association steps of monomers, which are thermodynamically unfavorable, representing the rate-limiting step in amyloid fibril formation in vitro. Once the nucleus (n-mer) has been formed, further addition of monomers to the nucleus becomes thermodynamically favorable, resulting in rapid extension of amyloid fibrils according to a first-order kinetic model, i.e., via the consecutive association of precursor proteins onto the ends of existing fibrils [14, 17, 18].

In the mechanism of amyloidogenesis from β2-m, natively folded proteins, partial unfolding of protein is prerequisite to its assembly into amyloid fibrils [3, 13, 19, 20]. The extension of
Figure 2. β₂-microglobulin-related (Aβ₂M) amyloid fibril extension in vitro. Sub-micellar concentration of sodium dodecyl sulfate (SDS) induces Aβ₂M amyloid fibrils extension at a neutral pH while micellar concentration induces amyloid fibril depolimerization in vitro. The amount of extended fibrils is measured by Thioflavin T (A), and observed by electron microscopy (B). Bar shows 250 nm.

Aβ₂M amyloid fibrils, as well as the formation of the fibrils from β₂-m are greatly dependent on the pH of the reaction mixture, with the optimum pH around 2.0-3.0 [13, 14]. At pH 2.5, where the extension of Aβ₂M amyloid fibrils is optimum, β₂-m loses much of the secondary and tertiary structures observed at pH 7.5 [13, 19]. Aβ₂M amyloid fibrils readily depolymerize into monomeric β₂-m at a neutral pH [19], however, low concentration of TFE [3] and sub-micellar concentration of SDS [4] induced Aβ₂M amyloid fibrils extension with changing conformation of β₂-m monomer and inhibiting depolymerization of amyloid fibrils at a neutral pH in vitro (Figure 2). While TFE and SDS are organic compounds, several biomolecules could induce Aβ₂M amyloidogenesis in vivo, such as apolipoprotein E, proteoglycans, glicosaminoglycans, type I collagen, non-esterified fatty acid, and lysophospholipids. [4-6, 21, 22]. For example, some lysophospholipids, especially lysophosphatidic acid (LPA) induces both amyloid fibril formation and fibrillogenesis.

3. Clinical implications

Serum amyloid A (SAA) and κ and λ light chains are seen in patients who undergo peripheral blood stem cell transplantation (PBSC) for multiple myeloma and other hematologic malignancies. The concentration of SAA and its light chains is correlated with tumor burden and disease activity. In patients with multiple myeloma, the plasma concentration of SAA is significantly higher than in healthy individuals and is directly related to the extent of bone destruction and the severity of the disease. The serum level of SAA can be used as a biomarker for monitoring disease activity and response to treatment. A cutoff level of 2 mg/L has been suggested for the screening of patients with multiple myeloma.
Amyloid fibril formation and extension at a neutral pH [5]. The mechanism of amyloidogenesis is due to make β₂-m monomer into partially unfolding the compact structure as well as stabilizing the extended fibrils in vitro. Clinically, plasma LPA concentration is higher in patients undergoing hemodialysis treatment as compared to healthy subjects [5]. It's unclear the local concentration of lysophospholipids in the lesion that Aβ₃M amyloid deposits, it may be reasonable to consider the reaction between β₂-m and lysophospholipids that are increased in chronic kidney disease (CKD) undergoing dialysis treatment. Joint tissues that Aβ₃M amyloid deposits at early stage in dialysis patients, contains many kinds of glycosaminoglycans and proteoglycans. Depolymerization of Aβ₃M amyloid fibrils at a neutral pH in vitro was inhibited dose-dependently by the presence of some glycosaminoglycans (heparin, dermatan sulfate or heparin sulfate) or proteoglycans (biglycan, decorin or keratan sulfate proteoglycan) [21]. In addition, some glycosaminoglycans, especially heparin, enhanced the Aβ₃M amyloid fibril extension induced by low concentration of TFE at a neutral pH [3]. These results suggest that some glycosaminoglycans and proteoglycans stabilize extended Aβ₃M amyloid fibrils possibly by binding directly to the surface of the fibrils in vivo. Heparin is widely used for the hemodialysis treatment as an anticoagulant. Although no significant difference in the prevalence of Aβ₃M amyloidosis was found between continuous ambulatory peritoneal dialysis patients and hemodialysis patients carefully matched for time on dialysis and age at the onset of dialysis [23], our study may suggest that heparin could exert a subtle effect for the development of Aβ₃M amyloidosis under some clinical conditions.

Those molecules are picked up from the results of in vitro amyloid fibril formation, extension, and depolymerization, and further studies will be needed to analyze the histological relationship between those biomolecules and Aβ₃M amyloid in the lesion.

2.4. Progress of bone disease after deposition of amyloid fibrils

It is not clearly understood the progress of bone disease after deposition of amyloid fibrils. Deposited amyloidosis induces compression that induced CTS and joint arthropathy. Also amyloid deposition induces local osteolysis that induced bone cysts and DSA. The progress through synovial inflammation and subsequent osteolastogenesis and/or osteoclast activation through three possible pathways: (i) indirect action of inflammatory cytokines through the expression in osteoblasts of receptor activator of nuclear factor-κB ligand/osteoprotegerin ligand (RANKL/OPGL), (ii) direct action of inflammatory cytokines, and (iii) RANKL/OPGL expression in inflammatory cells.

3. Clinical manifestations

3.1. Serum β₂-m levels in patients undergoing dialysis treatment

Advanced CKD induces the serum level of β₂-m to elevate due to the impaired metabolism and excretion in the kidney. The average serum concentration levels of β₂-m in patients undergoing dialysis is significantly higher compared to those in normal subjects (25–45 vs. 1–2 mg/L) [10, 24-27]. It is clearly understood that the impairment of metabolism in the kidney
is the main cause of fluid retention in HD patients; however, it is not clear whether the production of $\beta_2$-m is increased with CKD and/or dialysis treatment. However, a study shows that the amount of $\beta_2$-m on the surface of granulocytes, lymphocytes and monocytes in hemodialysis patients is higher than that in control subjects while mRNA expression of $\beta_2$-m in blood cells is no significant difference between them [28]. This result shows the possibility that increased binding of $\beta_2$-m to blood cells is one of major cause of retention of $\beta_2$-m in dialysis patients. Thus continuous higher serum levels of $\beta_2$-m could induced DRA after long-term dialysis treatment [24, 29].

3.2. Risk factors of DRA

Risk factors of DRA are (i) long-term dialysis treatment, (ii) initiation dialysis treatment in young age, (iii) hemodialysis treatment with low purity dialysate, (iv) use of low-flux dialysis membrane [30], while the pathogenesis of DRA with those risk factors is still incompletely understood. Recently it has trend to use high-flux dialysis membrane and high purity dialysate in hemodialysis treatment. However, progress of dialysis treatment as well as treatment for other diseases makes better survival of dialysis patients and older initiation of dialysis treatment. Thus long-term and old age dialysis patients increase, and DRA is still one of serious complications for patients undergoing dialysis treatment.

Serum level of $\beta_2$-m, precursor protein of DRA, increase in dialysis patients and is believed most important for onset and progress of DRA. While cross sectional study shows no relation between onset of DRA and serum level of $\beta_2$-m [24], DRA may be onset after accumulation of $\beta_2$-m with long duration of dialysis treatment [29].

3.3. Clinical manifestations

Long-term dialysis treatment for end-stage kidney disease often induces the $A\beta_2$-m amyloid deposition in mainly osteoarticular tissues that induces various disorders, such as CTS, DSA, and cystic bone lesions as well as in rarely systemic organs such as heart [31] and gastrointestinal tract [32] when disease is advanced. CTS is induced by the deposition of $A\beta_2$-m amyloid around synovium in carpal tunnel and the compression of median nerve. DSA is induced by the deposition of $A\beta_2$-m amyloid and the defect of bone in spine. It is radiographically characterized by severe narrowing of the intervertebral disk space and erosions as well as cysts of the adjacent vertebral plates. DSA lesions are mostly detected in the highly mobile areas, such as C5–C7 and L3–L5 [33]. Cystic lesions occur in bones, such as carpal and femur that $A\beta_2$-m amyloid deposition is found around them. Cystic lesions as well as mineral bone disorder associated with CKD increase the risk of bone fracture.

DRA, induce various osteo-articular disorders, is one of serious complications in patients undergoing long-term dialysis treatment even improvement of dialysis treatment such as dialysis membrane and dialysate [34, 35]. For example, we researched over a four year period 359 end-stage kidney disease patients undergoing dialysis treatment were admitted in our center for the treatment of their dialysis-related complications [34]. DSA was a major cause of hospital admission in the patients undergoing dialysis therapy for 20 years or more, and the

![Figure](https://example.com/figure.png)

Figure 1. Incidence rate of DRA in HD patients. The incidence rate of DRA over 20-24 years is higher than that in younger patients.
The incidence rate of histories of surgeries for osteoarticular disorders, related to DRA was 25.0, 66.0, and 77.8% in 20-24 years, 25-29 years, and 30 years or more after the initiation of dialysis therapy, respectively (Figure 3). In the patients undergoing dialysis therapy for 30 years or more, the incidence rate of histories of surgeries for CTS, DSA, and joint arthropathy was 72.2%, 50.0%, and 22.2%, respectively that indicated they had analogous histories of surgeries for various osteoarticular disorders (Figure 4). These results indicate that the frequency and severity of osteoarticular disorders which may be caused by DRA accelerated with the increasing duration of dialysis therapy especially for the patients undergoing dialysis therapy for 30 years or more.

Figure 3. The incidence rate of histories of surgeries for osteo-articular disorders, related to dialysis-related amyloidosis (DRA). The rate is 25.0, 66.0, and 77.8% in 20-24 years, 25-29 years, and 30 years or more after the initiation of dialysis therapy, respectively. In the patients undergoing dialysis therapy for 30 years or more, the rate for carpal tunnel syndrome (CTS), destructive spondyloarthropathy (DSA), and joint arthropathy was 72.2%, 50.0%, and 22.2%, respectively.
Case: Male
36 y.o.
Hemodialysis
41
Lt. CTS
48
Rt. CTS
Lumber DSA
Bil. Shoulder joint arthropathy
Lt. CTS
61
62
63
66
Cervical DSA

Pre-operation
Post-operation

Figure 4. A case of long-term dialysis patients complicated with various osteo-articular disorders related to dialysis-related amyloidosis (DRA). A man had end-stage kidney disease due to chronic glomerulonephritis and received hemodialysis treatment for 30 years. He had various DRA-related osteo-articular disorders, such as carpal tunnel syndrome (CTS), joint arthropathy, and destructive spondylarthropathy (DSA) that needed surgical treatment.

Next, we researched 102 patients undergoing dialysis treatment for 30 years or more in our related hospitals, and their complication of osteoarticular disorders. The age at initiation of dialysis therapy was 27.3 ± 7.7 years, and the duration of dialysis therapy was 32.3 ± 1.8 years. The surgery for CTS was done for 80 patients (76%) in 21.6 ± 5.5 years after the initiation of dialysis therapy for 17 patients in the inci teaching hospitals. However, in most serious patients, further studies on our study showed that DRA was the most common complication of the cons dialysis patient. Now use a new treatment since then.

In summary, which may in cases tre

4. Treat

Main purpose of the treatment is to prevent high-flux hemofiltration with dialyse and reduce β2-MG levels of 90% while using osteoporosis: osteoarticular disorder.

4.1. Hemo

The use of high-flux hemofiltration compared to the lower dose group. In
dialysis therapy. All of those patients received the surgeries more than 2 times, furthermore, some of them received more than 4 times for 30 years or more. The surgery for DSA was done for 17 patients (16%) in 27.1 ± 4.7 years after initiation of dialysis treatment. There is dissociation in the incidence of history of surgery for DSA between in our center [34] and in our related hospitals while that for CTS was similar. The main reason may be that our center is a university teaching hospital and severe patients are referred to our hospital. This is a major limitation, however, it should be remembered that one of the main causes for admission was DSA in the patients undergoing long-term dialysis therapy. Our results may suggest that DRA is one of most serious complications in the patients undergoing dialysis therapy for 30 years or more. Further study will be needed about the detail of DRA in the in long-term dialysis patients. In our studies, the main factor associated with osteoarticular disorders which may be caused by DRA was the duration of dialysis therapy despite the younger age at initiation of dialysis therapy [34]. Other risk factors, such as dialyzer and dialysate could not be considered because of the consistent improvements in the technologies from year to year. For example, long-term dialysis patients had used the low-flux dialyzer for several years since initiating therapy, but now use a high-flux dialyzer. Short-term patients however, have used the high-flux dialyzer since the initiation of dialysis therapy.

In summary of our clinical research, the frequency and seriousness of osteoarticular disorders which may be caused by DRA were accelerated with the duration of dialysis therapy, especially in cases treated for 30 years or more.

4. Treatment for DRA

Main purpose of treatment for DRA is a) to prevent the deposition of Aβ2-m amyloid fibrils in the lesions, and b) to relieve symptoms induced by Aβ2-m amyloid deposition. Remove β2-m with dialysis treatment and suppression of systemic/local inflammation are beneficial to prevent the deposition of Aβ2-m amyloid fibrils. Practically, it should be used biocompatible high-flux dialysis membrane and high purity dialysate in hemodialysis treatment. In addition, hemofiltration, hemodiafiltration, and use of β2-m adsorption column have much effect to reduce β2-m and to improve symptoms [36]. Non-steroidal anti-inflammatory drugs or low dose of steroid sometimes show relief of symptoms induced by Aβ2-m amyloid deposition while use of steroid for long duration has risk to induce adverse effect, such as infection and osteoporosis. Surgical treatments are needed when Aβ2-m amyloid deposition induces severe osteoarticular symptoms.

4.1. Hemodialysis/hemodiafiltration

The use of high-flux dialyzer membrane leads to a reduction in the serum level of β2-m as compared to using low-flux dialyzer membrane. In the HEMO Study [26], the predialysis serum β2-m level was lower in the high-flux membrane group than in the low-flux membrane group. In another study, switching of dialyzer from conventional to high-flux membrane reduced the predialysis serum β2-m level [37]. Clinically, Küchle et al [38] examined the effect
of polysulfone high-flux dialysis membrane in hemodialysis treatment, and showed less onset of CTS, arthropathy and bone cysts as well as lower concentration of serum β2-m as compare to use of low-flux dialysis membrane. The reason why high-flux membrane produces a lower level of serum β2-m is not only that it promotes better clearance, but that it also increases the binding of β2-m to blood cells, such as granulocytes, lymphocytes and monocytes [28]. High purity dialysate with low endotoxin reduced serum β2-m, pentosidine, C-reactive protein, and interleukin-6 [39] that probably accelerates Aβ2-m amyloid deposition.

Hemodiafiltration has better clearance of middle size molecules than HD and is known to reduce the risk of progression of DRA. A recent multicenter prospective randomized study revealed that on line HDF showed greater efficiency than HD with low-flux membrane in reducing the basal level of β2-m [40].

4.2. HD with β2-m adsorption column

A β2-m adsorption column has been developed as a way to directly eliminate serum β2-m. This adsorption column system is designed for direct hemoperfusion (Figure 5). Adsorption of β2-m by this column is a result both of hydrophobic and molecular size-dependent interactions between the ligand in the column and β2-m molecule. The effects of this column show the reduction rate; 60.0-78.9 %, the amount of adsorption; 157-300 mg, serum β2-m after treatment; 6.8-13.5 mg/L with single treatment [41-43].

Figure 5. A schematic representation of hemodialysis treatment with β2-m microglobulin (β2-m) adsorption column. The β2-m adsorption column is placed in series with the dialyzer, with blood flowing through the column first.
According to a prospective multicenter study, a β₂-m adsorption column that was placed in series with a polysulfone dialyzer increased serum β₂-m reduction in patients undergoing hemodialysis as compared to hemodialysis treatment without β₂-m adsorption column [42]. This study also showed improvements of DRA-related symptoms, such as joint pain and activity of daily living, and it may suggest that the column absorbs not only β₂-m, but also other molecules related to inflammation. Furthermore, a clinical study showed shrink the size of bone cysts when they are checked by X-ray [43].

4.3. Other kidney replacement therapies

A significant inverse relationship is observed between residual renal function and serum β₂-m level [44]. This suggests that peritoneal dialysis may keep lower serum levels of β₂-m because of better maintenance of intrinsic renal function, but not peritoneal function, than hemodialysis. However, the prevalence of histological DRA in peritoneal dialysis patients is not significantly different from that observed in a group of hemodialysis patients matched for age and dialysis duration [23]. End-stage kidney disease patients can do peritoneal dialysis only for 5-10 years, and it is difficult to discuss which treatment shows benefit to prevent DRA. A radical approach for DRA is kidney transplantation that reduces serum β₂-m, improves symptoms related to DRA and inhibits the progression [45]. The effects of kidney transplantation on DRA probably due to not only recover of kidney function but also effect of immunosuppression therapy.

4.4. Medical and surgical treatment

Use of steroid shows beneficial effect for the pain induced by DRA while surgical treatment will be needed for advanced CTS and DSA. However, DSA induces serious neurological symptoms and it is sometimes hard to relief them with surgery. For example, 95 of 865 patients undergoing dialysis treatment had surgeries for DSA, while rate of post-operative complications, such as infection and cardiac events, was much higher than those without DSA [46].

5. DRA, a part of chronic kidney disease-mineral and bone disorder

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a systemic disorder, which consists from abnormal levels of mineral-related biochemistry, bone abnormalities, and soft tissue calcification [47]. Various types of bone abnormalities are observed in CKD patients, such as high-turnover bone disease and osteomalacia. DRA causes bone abnormalities in patients undergoing dialysis treatment. Bone cyst, joint arthropathy, and DSA are frequency and specifically found in patients especially undergoing long-term hemodialysis therapy [48]. It remains controversial whether DRA and related osteopathy should be included in CKD-MBD. However, DRA is at least closely involved with CKD-MBD, from the view point of preventing osteoarticular complications in dialysis patients (Figure 6).
Figure 6. Dialysis-related amyloidosis (DRA) in chronic kidney disease-mineral bone disorder (CKD-MBD). CKD-MBD as well as DRA contains various types of bone abnormalities. Furthermore, β2-microglobulin/DRA may be involved with cardiovascular disease, bone fracture, and mortality which are clinical outcomes of CKD-MBD. In the viewpoint of bone abnormalities, DRA may be related strongly with CKD-MBD.

CKD-MBD contains various types of bone abnormalities, such as high-turnover bone disease, osteomalacia, and adynamic bone disease. DRA, such as bone cyst, joint arthropathy and DSA, also causes bone abnormalities and is included in renal osteodystrophy. Recently, some groups reported the relation between serum levels of β2-m and atherosclerosis [49] or mortality [26], thus β2-m/DRA may be involved with cardiovascular disease, bone fracture, and mortality which are clinical outcomes of CKD-MBD. In the viewpoint of bone abnormalities, DRA related osteopathy may enhance the serious bone disorder, such as bone fractures and DSA, in the presence of other bone abnormalities, such as high-turnover bone disease and osteomalacia. DRA is a serious complication in patients who are receiving long-term dialysis therapy and obviously seems more harmful than other osteodystrophy in terms of maintenance of their ADL and quality of life. Further studies will be needed for this assumption.

6. Conclusion

DRA is still one of major and serious complications in end-stage kidney disease patients undergoing long-term dialysis treatment. Several biomolecules that may relate to Αββ₂M amyloidogenesis are raised from in vitro studies, and that will be needed to investigate the...
involvement in amyloid deposition in vivo. These findings will develop more beneficial prevention and treatment for DRA as well as improvement of dialysis treatment.

**Author details**

Suguru Yamamoto, Junichiro James Kazama, Hiroki Maruyama and Ichiei Narita

Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Blood Purification Center, Niigata University Medical and Dental Hospital, Niigata, Japan

Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan

**References**


Dialysis-Related Amyloidosis: Pathogenesis and Clinical Features in Patients Undergoing Dialysis Treatment

http://dx.doi.org/10.5772/53390


Amyloidosis
http://dx.doi.org/10.5772/46140
Edited by Dali Feng

Contributors
Suguru Yamamoto, Junichiro Kazama, Hiroki Maruyama, Ichiei Narita, Jozélio de Carvalho, Tadashi Nakamura, Takeshi Kuroda, Keisuke Hagihara, Syota Kagawa, Junsuke Arimitsu, Yuki Kishida, Hesam Hashemian, Sudhir Kushwaha, Maarit Tanskanen, Fernando L Palhano, Dali Feng

Published by InTech
Janeza Trdine 9, 51000 Rijeka, Croatia

Copyright © 2013 InTech
All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. However, users who aim to disseminate and distribute copies of this book as a whole must not seek monetary compensation for such service (excluded InTech representatives and agreed collaborations). After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source.

Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book.

Publishing Process Manager Iva Simcic
Technical Editor InTech DTP team
Cover InTech Design team

First published June, 2013
Printed in Croatia

A free online edition of this book is available at www.intechopen.com
Additional hard copies can be obtained from orders@intechopen.com

Amyloidosis, Edited by Dali Feng
p. cm.

P239